Chest
Original ResearchPulmonary Vascular DiseaseSurvival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era
Section snippets
Study Patients
We performed a retrospective cohort study of consecutive patients who received a diagnosis of IPAH or CTDPAH between 2007 and 2009 at five national referral pulmonary vascular centers in China, located in the northern, northeastern, central, southern, and eastern regions, according to a standardized diagnostic and treatment approach for PAH. Details of all newly diagnosed incident cases were recorded in a database at the time of diagnosis before any targeted treatments for PAH were started. The
Demographic Characteristics
A total of 276 patients were treated, including 173 patients who received a diagnosis of IPAH and 103 patients who received a diagnosis of CTDPAH. In patients with CTDPAH, systemic lupus erythematosus, scleroderma, Sjögren syndrome, mixed connective tissue disease, and arthritis accounted for 38%, 22%, 11%, 10%, and 4% of the population, respectively. The baseline demographic and clinical characteristics of the two etiologic groups are shown in Table 1. Most patients in both groups were women.
Discussion
The present study is one of the largest cohort studies from China concerning the clinical characteristics and survival of patients with PAH in the modern treatment era. Several clinical trials in Chinese patients with PAH have demonstrated the benefit of newer targeted therapies.16, 17 Therefore, it is important to examine the outcome of targeted treatment with these agents for various PAH subtypes in China.
In an earlier study, Schachna et al18 identified increasing age as a risk factor for PAH
Acknowledgments
Author contributions: Dr Zhang: contributed to recruiting the patients, drafting the submitted article, interpreting the data, performing the statistical analysis of the data, and approving the final manuscript.
Dr Dai: contributed to recruiting the patients, drafting the submitted article, interpreting the data, performing the statistical analysis of the data, and approving the final manuscript.
Dr Xie: contributed to enrolling the subjects, data acquisition, and approving the final manuscript.
References (28)
- et al.
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
J Am Coll Cardiol
(2002) - et al.
Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension
Chest
(2007) - et al.
The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III
Value Health
(2009) - et al.
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Portopulmonary hypertension: a tale of two circulations
Chest
(2003) - et al.
Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension
J Heart Lung Transplant
(2010) - et al.
Age and risk of pulmonary arterial hypertension in scleroderma
Chest
(2003) - et al.
Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension
Am J Cardiol
(1999) - et al.
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis
Chest
(2003) - et al.
Determinants of right ventricular ejection fraction in pulmonary arterial hypertension
Chest
(2009)
Primary pulmonary hypertension
N Engl J Med
Pulmonary arterial hypertension
N Engl J Med
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy
Circulation
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
Eur Heart J
Cited by (0)
Drs Zhang and Dai contributed equally to this article.
Funding: This study was sponsored by the Shanghai Pujiang Program [Grant 08PJ1408600] and the Shanghai Science and Technology Division of Non-governmental International Cooperation Projects [Grant 08410701600].
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).